<DOC>
	<DOCNO>NCT01251822</DOCNO>
	<brief_summary>This study compare efficacy safety polyethylene glycol ( PEG ) 3350 prucalopride treatment chronic constipation female . A total 240 patient randomly allocate treatment one agent . The study consist 14-day run-in period , treatment subsequently administer 28 day daily basis . During study , patient fill stool diary , sample faeces collect , colonic transit time measure prior therapy , day 22 28 treatment . The proportion patient normalise bowel movement ( three spontaneous movement ) last week study ( day 22 28 treatment ) compare treatment .</brief_summary>
	<brief_title>Comparator Study PEG 3350 Versus Prucalopride Females With Chronic Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Polyethylene glycol 3350</mesh_term>
	<criteria>1 . Patient 's write informed consent must obtain prior inclusion . 2 . Female patient age 18 75 year chronic constipation confirm runin period . 3 . Patient history selfreported chronic constipation least 6 month satisfied laxative past . Chronic constipation define ROME III criterion ( Drossman DA et al. , 2006 ; Drossman DA , 2006 ) characterise : &lt; 3 successful bowel movement per week least 1 follow symptom present least 3 month prior enrolment : Straining least 25 % defecation . Lumpy hard stool least 25 % defecation . Sense incomplete evacuation least 25 % defecation . Sensation anorectal blockage least 25 % defecation . Manual manoeuvre facilitate least 25 % defecation . 4 . Less 3 SCBMs last week runin period . 5 . Willing able follow entire procedure comply study instruction . 1 . History evidence organic disease large bowel , intestinal perforation obstruction due structural functional disorder gut wall , ileus , severe inflammatory condition intestinal tract Crohn 's disease ulcerative colitis , toxic megacolon occlusive subocclusive syndrome . 2 . Abdominal pain unknown cause . 3 . Known allergy PEG 3350 , prucalopride know hypersensitivity study medication ingredient . 4 . Drug alcohol abuse ( recent history within previous 12 month ) . 5 . Pregnant lactate female . 6 . Severe acute disease within last 2 week prior start study base Investigator 's judgement . 7 . Use : Any oral purgatives/laxatives prokinetics within last 14 day prior dose study . Any opioids , anticholinergic , tricyclic antidepressant , monoamineoxidase inhibitor iron preparation within last 4 week prior dose . Any calciumantagonists , betablockers diuretic within last 4 week prior dose . Other investigational drug prescribe medication affect gastrointestinal function antispasmodic , drug affect motility ( e.g . erythromycin ) , anthraquinones , ondansetron 5hydroxytryptamine3 ( 5HT3 ) antagonist . Any medication opinion investigator could interfere principal function gastrointestinal tract . 8 . Insufficient documentation chronic constipation runin period . 9 . Diarrhoea runin period . 10 . Anamnesis/medical history clinically relevant finding gastrointestinal tract proctoscopy , colonoscopy , sigmoidoscopy computer tomography , condition Investigator 's opinion , may put patient significant risk , may confound study result may interfere significantly result study . 11 . Participation another clinical study drug device parallel less 90 day study entry previous participation study . 12 . Gastrointestinal surgery within last 6 month prior start study . 13 . Malignant tumour within last 5 year prior start study . 14 . Uncontrolled blood pressure terminal cardiac , liver and/or kidney disease . 15 . Patient diagnosis evidence follow disease : hypothyroidism , diabetes mellitus , porphyria , pituitary gland insufficiency , pheochromocytoma , glucagonoma , neurological disease ( e.g . Hirschprung diseases , neurofibromatosis , Chagas diseases , stroke , autonomous neuropathy , intestinal pseudoobstruction , multiple sclerosis , medullar injury , Parkinson diseases , ShyDrager syndrome ) , collagenosis , vasculitis , myopathy ( e.g . sclerodermatitis , amyloidosis , dermatomyositis ) , intoxication heavy metal ( e.g . lead , phosphorus , arsenic , mercury ) . 16 . Patients know HIV infection . 17 . Woman childbearing potential , use willing use medically reliable method contraception entire study duration , oral , injectable , implantable contraceptive , intrauterine contraceptive device , unless surgically sterilised/hysterectomised criterion consider sufficiently reliable Investigator individual case .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>